
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
— Approval based on results of two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy — ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, […]

